With unrestricted educational grant from

Size: px
Start display at page:

Download "With unrestricted educational grant from"

Transcription

1 HOTEL MAKSOUD PLAZA SÃO PAULO SP BRASIL OCTOBER 22-23, 2009

2 Organization With unrestricted educational grant from

3 As the President of the Brazilian Society of Internal Medicine and the Brazilian Clinical Research Institute (BCRI) I am honored to welcome you to the 2 nd. International Symposium of Thrombosis and Anticoagulation ISTA The main purpose of this symposium is to discuss the most recent evidence on thrombosis and anticoagulation, including new agents under development and novel diagnostic tools in the field. The focus is to understand how to better apply the evidence into clinical practice so that the patients will gain and you will enhance the quality of care you offer your patients. This meeting provides a unique opportunity to witness the latest knowledge in this field. The clinical aspects including the most update treatments are our major objective in order to offer you concise answers that will help in the patient management on a day-by-day basis. I Hope you enjoy this scientific program and take advantage of the presence of our expert national and international faculty. Antonio Carlos Lopes, MD, PhD, FACP Brazilian Society of Internal Medicine President

4

5 Co-Chairs Becker, Richard C. MD Lopes, Renato D. MD, MHS, PhD Federal University of Sao Paulo (UNIFESP-EPM) International Faculty Alexander, John H. Garcia, David University of New Mexico (USA) Granger, Christopher B. Handller, Allison Jolicoeur, E. Marc Montreal Heart Institute (Canada) Newby, L. Kristin Pieper, Karen S. National Faculty Baruzzi, Antonio Claudio Carvalho, Antonio Carlos Chamone, Dalton de Alencar F. Guimarães, Hélio Penna Lopes, Antonio Carlos Machado, Fabio Santana Timerman, Ari

6 Scientific Program OCTOBER 22, :00 09:10 Opening Antonio Carlos Lopes, Richard C. Becker, and Renato D. Lopes SESSION I President: Christopher B. Granger 09:10 09:30 Update in Thrombosis and Anticoagulation in Clinical Practice Richard C. Becker 09:40 10:00 Biomarkers of Thrombosis - How and Which one to Use? L. Kristin Newby 10:10 10:30 Anticoagulation in Acute Coronary Syndromes Ari Timerman 10:30 10:50 Coffee Break 10:50 11:10 Triple Therapy - A Management Dilemma Renato D. Lopes 11:20 11:40 Stroke: Should We use Antithrombotics? When and How? Fabio Santana Machado 11:40 12:00 Challenging Cases David Garcia 12:00 14:00 Break SESSION II President: E. Marc Jolicoeur 14:00 15:20 Thrombosis in: Diabetes: L. Kristin Newby Atrial Fibrillation: John H. Alexander Dyslipidemia: Christopher B. Granger Heart Failure/Hypertension: Antonio Carlos Carvalho 15:30 15:50 Management of Bleeding Episodes in Patients receiving Antithrombotic Therapy David Garcia 16:00 16:30 Coffee Break 16:30 17:00 Design Issues and Statistical Considerations around Clinical Research Karen Pieper 17:10 17:40 Challenging Cases Renato D. Lopes / E. Marc Jolicoeur

7 OCTOBER 23, 2009 SESSION III President: Antonio Carlos Lopes 09:00 09:20 VTE prophilaxis in Medical Patients Renato D. Lopes 09:25 09:55 Treatment for VTE Dalton de Alencar F. Chamone 10:00 10:20 Post-thrombotic Syndrome: Epidemiology and Management Richard C. Becker 10:20 10:40 Coffee Break 10:40 11:10 Predicting Cancer Patients at Risk for Venous Thromboembolism: Strategies for Prophylaxis David Garcia 11:15 11:45 Diagnosis and Management of Pulmonary Embolism Antonio Claudio Baruzzi 11:50 12:10 How to Better Interpret the Medical Literature? Karen Pieper 12:15 12:45 Challenging Cases L. Kristin Newby 12:45 14:00 Break SESSION IV President: Christopher B. Granger 14:00 14:20 Globalization of Clinical Research John H. Alexander 14:30 15:00 Anticoagulation in Special Patient Populations E. Marc Jolicoeur 15:10 15:30 Anticoagulation in Intensive Care Units Hélio Penna Guimarães 15:40 16:00 Coffee Break 16:00 16:20 The Latest ACCP Antithrombotic Therapy Guidelines: Important Changes that may Impact Clinical Practice David Garcia 16:30 16:50 Importance of Academic Coordinating Center in Clinical Trials in Thrombosis Allison Handller 17:00 17:30 Challenging Cases Renato D. Lopes / E. Marc Jolicoeur

8 SBCM President and Co-Chairs Antonio Carlos Lopes, MD, PhD, FACP 4 Full Professor of Internal Medicine, Federal University of São Paulo - Paulista School of Medicine 4 Full Professor of Emergency Medicine, Federal University of São Paulo - Paulista School of Medicine 4 PhD - Cardiology, Federal University of São Paulo Paulista School of Medicine 4 President of the Brazilian Society of Internal Medicine 4 President of the Brazilian Clinical Research Institute (BCRI) 4 Fellow of the American College of Physicians Richard C. Becker, MD 4 Professor of Medicine. Divisions of Cardiology and Hematology, Department of Medicine - Duke University Medical Center 4 Director of the Duke Cardiovascular Thrombosis Center Duke Clinical Research Institute (DCRI) 4 Co-director of the Advanced Biomarkers Program Duke Clinical Research Institute (DCRI) Renato Delascio Lopes MD, MHS, PhD 4 Adjunct Professor - Division of Cardiology, Department of Medicine - Duke University Medical Center 4 Assistant Director - Clinical Research Fellowship Program Duke Clinical Research Institute (DCRI) 4 Assistant Professor - Department of Internal Medicine Federal University of Sao Paulo - Paulista School of Medicine 4 Executive Director - Brazilian Clinical Research Institute (BCRI)

9 Invited Speakers Christopher B. Granger, MD, FACC 4 Professor of Medicine - Division of Cardiology, Department of Medicine - Duke University Medical Center 4 Director, Cardiac Care Unit - Duke University Medical Center 4 Co-Director of Cardiovascular Clinical Trials Duke Clinical Research Institute L. Kristin Newby, MD, MHS 4 Associate Professor - Division of Cardiology, Department of Medicine - Duke University Medical Center 4 Co-director of the Cardiac Care Unit Duke University Hospital 4 Co-director of the Advanced Biomarkers Program Duke Clinical Research Institute (DCRI) John Alexander, MD, MHS, FACC 4 Associate Professor - Division of Cardiology, Department of Medicine - Duke University Medical Center 4 Director of Early Phase Cardiovascular Research Duke Clinical Research Institute (DCRI) 4 Medical director of Site-Based Clinical Research in Cardiovascular Medicine Duke University Medical Center David Garcia, MD 4 Associate Professor - Department of Internal Medicine Division of Hematology/Oncology University of New Mexico Health Sciences Center 4 Director of Cancer and Thrombosis at the University of New Mexico Cancer Center - Director of the Anticoagulation Management Service at University Hospital

10 Invited Speakers E. Marc Jolicœur, MD, MSc, FRCP 4 Assistant Professor - Division of Cardiology, Department of Medicine - University of Montreal 4 Research Associate, University of Montreal Karen S. Pieper, MS 4 Associate Director for Faculty and Fellow Affairs and Clinical Trials Statistical Operations. Duke Clinical Research Institute (DCRI) Allison Handller RN, BSN, MS 4 Senior Project Leader Cardiovascular Devices Phase III/IV Cardiovascular Mega trials Duke Clinical Rsearch Institute (DCRI) Antonio Carlos Carvalho, MD, PhD, FACC 4 Full Professor of Cardiology, Federal University of São Paulo - Paulista School of Medicine 4 PhD - Cardiology, Federal University of São Paulo - Paulista School of Medicine 4 Scientific Director of the Brazilian Clinical Research Institute (BCRI) 4 Fellow of the American College of Cardiology Dalton de Alencar Fischer Chamone, MD, PhD 4 Full Professor of Hematology and Hemotherapy, São Paulo University Medical School 4 PhD - Hematology and Hemottherapy, University of Louvain, Belgium 4 Associate Professor, São Paulo University Pharmaceutical Sciences School

11 Ari Timerman, MD, PhD 4 Assistant Professor of Cardiology, ABC Foundation School of Medicine, 4 PhD - Cardiology, São Paulo University Medical School 4 Head of the Emergency and Intensive Therapy Division, Dante Pazzanese Institute of Cardiology 4 President of the Cardiopulmonary Resuscitation Division of the Dante Pazzanese Institute of Cardiology 4 Head Professor of the TIC5007, Cardiovascular Emergencies of the Postgraduate Program USP/IDPC Medicine/Technology and Intervention in Cardiology Antonio Claudio Baruzzi, MD, PhD 4 PhD - Cardiology, Institute of the Heart, São Paulo University Medical School 4 Physician of the Intensive Care Center, Albert Einstein Hospital Fabio Santana Machado, MD 4 Medical Coordinator of the Neurosurgical ICU of the Neurosurgery, São Paulo University Medical School 4 Collaborator Professor of the Internal Medicine, São Paulo University Medical School 4 Physician of the Neuro-Intensive Care Unit, Sírio Libanês Hospital Hélio Penna Guimarães, MD 4 Assistant Professor of Internal Medicine, Federal University of São Paulo - Paulista School of Medicine 4 President of the Chapter of Emergency Medicine of the Brazilian Society of Internal Medicine 4 Medical Coordinator, Teaching, Training and Simulation Center, Heart Hospital 4 Financial Director of the Brazilian Clinical Research Institute (BCRI)

12 Organization Support With unrestricted educational grant from Symposium Secretariat Caixa Postal: CEP: São Paulo SP Fax: [email protected]

Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media

Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban

More information

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of

More information

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban

More information

EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention in Patients with Atrial Fibrillation

EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention in Patients with Atrial Fibrillation Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention

More information

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients

More information

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment

More information

How To Get A Dose Of Bayer Healthcare'S Oral Anticoagulant, Xarelto

How To Get A Dose Of Bayer Healthcare'S Oral Anticoagulant, Xarelto News Release FOR UK HEALTHCARE MEDIA ONLY Bayer HealthCare Bayer plc Bayer House Strawberry Hill Newbury Berkshire, RG14 1JA www.bayer.co.uk Bayer s Xarelto (rivaroxaban) Recommended by CHMP for EU Approval

More information

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Late-Breaking Science at ESC Congress 2015: New Real-World Evidence Reaffirms

More information

Thrombosis and Hemostasis

Thrombosis and Hemostasis Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism

More information

Investor News. Not intended for U.S. and UK media

Investor News. Not intended for U.S. and UK media Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism

More information

Center of Excellence in Naturopathic Cardiovascular Medicine

Center of Excellence in Naturopathic Cardiovascular Medicine Introducing the Center of Excellence in Naturopathic Cardiovascular Medicine The Heart & Lung Wellness program at Center for Natural Medicine and National College of Natural Medicine WHO WE ARE A Center

More information

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics

More information

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38 Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac

More information

From Concept to a Published Paper - a guide to excellence in Medical Research.

From Concept to a Published Paper - a guide to excellence in Medical Research. The Course Directors of the New Frontiers in Interventional Cardiology (NFIC), Krakow Cardiovascular Research Institute (KCRI) and Proper Medical Writing (PMW) would like to welcome you to the seminar:

More information

June 2014 CURRICULUM VITAE. Peter E. Friedell, M. D. FACP. 2850 S. Wabash Suite 203. Chicago, Illinois

June 2014 CURRICULUM VITAE. Peter E. Friedell, M. D. FACP. 2850 S. Wabash Suite 203. Chicago, Illinois CURRICULUM VITAE June 2014 Peter E. Friedell, M. D. FACP. 2850 S. Wabash Suite 203 Chicago, Illinois 60616 312-808-0621 office 312-505-5106 cell 815-328-3833 fax [email protected] Personal: Date of Birth

More information

Prior Authorization Guideline

Prior Authorization Guideline Guideline Guideline Name Formulary Xarelto (rivaroxaban) UnitedHealthcare Community & State Approval Date 0/0/203 Revision Date 8//204 Technician Note: CPS Approval Date: /5/20; CPS Revision Date: 8/20/204

More information

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78

More information

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November

More information

Medication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015

Medication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Medication Policy Manual Policy No: dru313 Topic: Eliquis, apixaban Date of Origin: July 12, 2013 Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Effective Date: August 1, 2014 IMPORTANT

More information

21st Annual OSF Cardiovascular Symposium

21st Annual OSF Cardiovascular Symposium 21st Annual OSF Cardiovascular Symposium new waves in cardiac electrophysiology saturday 18 october 2014 7:00 a.m. 4:00 p.m. embassy suites conference center east peoria, illinois OBJECTIVES Overall Program:

More information

Bringing Science to Clinical Practice: BEST OF ACC 2015

Bringing Science to Clinical Practice: BEST OF ACC 2015 MAY 29 30, 2015 Eden Roc Miami Beach Bringing Science to Clinical Practice: BEST OF ACC 2015 COURSE DIRECTORS Robert O. Bonow, MD, MACC G. William Dec Jr., MD, FACC COURSE CO-DIRECTORS Akshay S. Desai,

More information

2014 Emerging Faculty Participants

2014 Emerging Faculty Participants Nazem Akoum, MD, FACC Assistant Professor of Medicine, Clinical Cardiac Electrophysiology EPIC EMR Cardiology Liaison University of Utah Health Sciences [email protected] Areas of Interest: Cardiac

More information

Minimally Invasive Cardiac Surgery

Minimally Invasive Cardiac Surgery 3rd Annual Bakken Symposium Minimally Invasive Cardiac Surgery December 7 & 8, 2009 Mayo Auditorium, COURSE DIRECTORS: Kenneth K. Liao, MD, PhD James D. St. Louis, MD Presented by Department of Surgery

More information

7th annual ConFerenCe location

7th annual ConFerenCe location Sponsors 7th Annual WOMEN and Ischemic Heart Disease Symposium Friday, April 19, 2013 Offered in cooperation with the California Chapter of the American College of Cardiology and WomenHeart: The National

More information

CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. San Diego, California San Diego Marriott Marquis & Marina October 3 5, 2014. Participating Faculty

CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. San Diego, California San Diego Marriott Marquis & Marina October 3 5, 2014. Participating Faculty CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE San Diego, California San Diego Marriott Marquis & Marina October 3 5, 2014 Participating Faculty Hector O. Ventura, MD, FACC Section Head, Cardiomyopathy and

More information

CHAPTER. 9th Annual Meeting October 12, 2013 8:00 am - 4:30 pm University of Kentucky Albert B. Chandler Hospital Auditorium Lexington, Kentucky

CHAPTER. 9th Annual Meeting October 12, 2013 8:00 am - 4:30 pm University of Kentucky Albert B. Chandler Hospital Auditorium Lexington, Kentucky Kentucky CHAPTER 9th Annual Meeting October 12, 2013 8:00 am - 4:30 pm Albert B. Chandler Hospital Auditorium Lexington, Kentucky Coronary Pathologies: Atherosclerosis and Beyond Please join your fellow

More information

Gruppo di lavoro: Malattie Tromboemboliche

Gruppo di lavoro: Malattie Tromboemboliche Gruppo di lavoro: Malattie Tromboemboliche 2381 Soluble Recombinant Thrombomodulin Ameliorates Hematological Malignancy-Induced Disseminated Intravascular Coagulation More Promptly Than Conventional Anticoagulant

More information

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological

More information

Brooklyn Stroke Symposium 2015

Brooklyn Stroke Symposium 2015 Brooklyn Stroke Symposium 2015 May 28, 2015 Brooklyn Public Library Grand Army Plaza Sponsored by Keynote Presentations Sleep Apnea and Stroke: More than a Snore Devin L. Brown, M.D., M.S. Professor of

More information

Duke Regional Diabetes Symposium 2012

Duke Regional Diabetes Symposium 2012 Duke Regional Diabetes Symposium 2012 July 13, 2012 8:30 AM 4:30 PM North Carolina Research Campus David H. Murdock Core Laboratory Building First Floor Event Room 150 Research Campus Drive Kannapolis,

More information

ABOUT XARELTO CLINICAL STUDIES

ABOUT XARELTO CLINICAL STUDIES ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the

More information

2012 Innovations in Heart Failure and Pulmonary Hypertension

2012 Innovations in Heart Failure and Pulmonary Hypertension ALLEGHENY GENERAL HOSPITAL CARDIOVASCULAR INSTITUTE PRESENTS 2012 Innovations in Heart Failure and Pulmonary Hypertension Friday, September 28, 2012 Marriott Pittsburgh City Center Pittsburgh, Pennsylvania

More information

EXHIBITOR PROSPECTUS

EXHIBITOR PROSPECTUS American Stroke Association 4 th Annual Connecticut Stroke Conference: TRUMBULL MARRIOTT MERRITT PARKWAY, TRUMBULL, CT EXHIBITOR PROSPECTUS To Whom It May Concern: On behalf of the American Stroke Association,

More information

Cardiac Care Associates 2014 Annual Meeting

Cardiac Care Associates 2014 Annual Meeting Cardiac Care Associates 2014 Annual Meeting March 7, 2014 Villa Christina Restaurant at Perimeter Co-provided by the American College of Cardiology Foundation and The Georgia Chapter of the American College

More information

CARDIOLOGY UPDATE 2004

CARDIOLOGY UPDATE 2004 Division of Cardiology Department of Medicine University of California, San Francisco School of Medicine CARDIOLOGY UPDATE 2004 September 30 - October 2, 2004 Carmel Valley Ranch Carmel, California University

More information

23 rd Annual Conference on Cardiovascular Nursing

23 rd Annual Conference on Cardiovascular Nursing 23 rd Annual Conference on Cardiovascular Nursing Thursday, April 11, 2013 7:00 am - 3:45 pm Boston Marriott Newton Newton, MA Keynote Speaker Marvin A. Konstam, MD Chief Physician Executive, The CardioVascular

More information

EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012

EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012 EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF Recorded Webcast Update for Analysts and Investors March 26, 2012 1 Webcast Presentation Agenda EINSTEIN PE Clinical Trial

More information

ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease

ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease Diabetes, prediabetes and cardiovascular disease Classes of recommendations Levels of evidence Recommended treatment targets for patients with diabetes and CAD Definition, classification and screening

More information

Investor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S.

Investor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S. Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint

More information

DVT/PE Management with Rivaroxaban (Xarelto)

DVT/PE Management with Rivaroxaban (Xarelto) DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular

More information

Eliquis. Policy. covered: Eliquis is. indicated to. reduce the. therapy. Eliquis is. superior to. of 32 to. Eliquis is AMPLIFY. nonfatal. physicians.

Eliquis. Policy. covered: Eliquis is. indicated to. reduce the. therapy. Eliquis is. superior to. of 32 to. Eliquis is AMPLIFY. nonfatal. physicians. Eliquis (apixaban) Policy Number: 5.01.573 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Eliquis when it is determined to be medically necessary

More information

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG

More information

Anticoagulation at the end of life. Rhona Maclean [email protected]

Anticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk Anticoagulation at the end of life Rhona Maclean [email protected] Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION

STROKE PREVENTION IN ATRIAL FIBRILLATION STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients

More information

INTERPRETING CLINICAL DATA: Highlights From ASCO 2016

INTERPRETING CLINICAL DATA: Highlights From ASCO 2016 INTERPRETING CLINICAL DATA: Highlights From ASCO 2016 SATURDAY, JUNE 25, 2016 Detroit Marriott - Troy, MI AGENDA Time Topic Speaker 7:30 am Registration and Continental Breakfast 8:00 am Opening Remarks/Welcome

More information

INTRODUCTION. For supporting information, we invite you to explore. Our Corporate Website. and its Media Center

INTRODUCTION. For supporting information, we invite you to explore. Our Corporate Website. and its Media Center INTRODUCTION PRESENT e-learning Systems is both a pioneer in the combining of online social networking with CME medical education, and using these web properties and opt-in members lists to deliver effective

More information

HHT Center of Excellence The University of Texas, Southwestern. Dallas, Texas

HHT Center of Excellence The University of Texas, Southwestern. Dallas, Texas HHTCenterofExcellence TheUniversityofTexas,Southwestern Dallas,Texas Medical Director, Pulmonary Consultant Daniel Goodenberger, M.D. Professor of Medicine Phone (214)857-0409 FAX (214)857-1457 e-mail:

More information

Cardiac Rehabilitation: Strategies Approaching 2020

Cardiac Rehabilitation: Strategies Approaching 2020 ACC Banff 2015 Cardiac Rehabilitation: Strategies Approaching 2020 James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Libin Cardiovascular

More information

A C C O M M O D A T I O N S D I R E C T I O N S. Exhibitor tables will be accessible at 7:30 a.m.

A C C O M M O D A T I O N S D I R E C T I O N S. Exhibitor tables will be accessible at 7:30 a.m. R E g I S T R AT I O N I N F O R M AT I O N There is a $55 fee for Christiana Care Health System (CCHS) employees ($75 day of registration, if seating permits), $75 fee for non-cchs employees ($95 day

More information

Stroke/VTE Quality Measure Build for Meaningful Use Stage 1

Stroke/VTE Quality Measure Build for Meaningful Use Stage 1 Stroke/VTE Quality Measure Build for Meaningful Use Stage 1 Presented by Susan Haviland, BSN RN Senior Consult, Santa Rosa Consulting Meaningful Use Quality Measures Centers for Medicare and Medicaid Services

More information

Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital

Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital Jonathan Sykes MD, CMIO Jacalyn Liebowitz RN, MBA,NEA-BCFACHE VP Care Continuum Allegiance Health - Jackson, MI DISCLAIMER:

More information

AnMed Health Disparities Dashboard

AnMed Health Disparities Dashboard AnMed Health Quick Facts 588 Bed Acute Care System Level II Trauma Center Emergency Department visits: 112,329 Admissions: 23,489 Active Medical Staff: 455 Employees: 3,511 Source : CY2013 Setting the

More information

FRIDAY, FEBRUARY 26, 2016 7:15 A.M. TO 3:15 P.M.

FRIDAY, FEBRUARY 26, 2016 7:15 A.M. TO 3:15 P.M. CEDARS-SINAI HYPERTENSION CENTER 2016 Clinical Highlights Symposium FRIDAY, FEBRUARY 26, 2016 7:15 A.M. TO 3:15 P.M. CONFERENCE LOCATION Harvey Morse Conference Center 8701 Gracie Allen Drive Plaza Level,

More information

2016 Cardiovascular Update

2016 Cardiovascular Update 2016 Cardiovascular Update March 18, 2016 Villa Christina Restaurant at Perimeter Jointly Provided by the American College of Cardiology Foundation and The Georgia Chapter of the American College of Cardiology

More information

Heart Failure: From Prevention to Intervention

Heart Failure: From Prevention to Intervention Sharp HealthCare Presents Heart Failure: From Prevention to Intervention Saturday, May 16, 2015 DoubleTree by Hilton Hotel San Diego - Mission Valley San Diego, Calif. As medical professionals, we know

More information

Establishing a Course of Excellence. Duvall, WA 98019 Or Complete This Form and Return. PH: 425.844.9019 to Gaffney Events

Establishing a Course of Excellence. Duvall, WA 98019 Or Complete This Form and Return. PH: 425.844.9019 to Gaffney Events Office Phone: Mobile Phone: TYPE OF PRACTICE Please Specify REGISTRATION FEES: PRIOR TO 6/1/16 $150 DPM / Physician $50 Student $75 Nurse / PA / Technician / Resident $150 Industry Representative REGISTRATION

More information

Backgrounder. Current anticoagulant therapies

Backgrounder. Current anticoagulant therapies Backgrounder Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Current anticoagulant therapies Anticoagulant drugs have significantly reduced the risk of thromboembolic events

More information

EXHIBITOR PROSPECTUS

EXHIBITOR PROSPECTUS American Heart Association Newton Marriott, Newton, MA EXHIBITOR PROSPECTUS To Whom It May Concern: On behalf of the American Heart Association and the members of the Boston Cardiovascular Nursing committee,

More information

New Oral Anticoagulants. How safe are they outside the trials?

New Oral Anticoagulants. How safe are they outside the trials? New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants

More information

May 20, 2016. May 21, 2016. The 5th Annual Comprehensive Stroke and Neurocritical Care Symposium. Comprehensive Stroke Symposium

May 20, 2016. May 21, 2016. The 5th Annual Comprehensive Stroke and Neurocritical Care Symposium. Comprehensive Stroke Symposium The 5th Annual Comprehensive Stroke and Neurocritical Care Symposium May 20, 2016 Comprehensive Stroke Symposium May 21, 2016 Emergency Neurological Life Support Course and Certification The Richmond Marriott

More information

CURRICULUM VITAE. NAME: Stephen Harold Arnold Hernandez, PhD, RN

CURRICULUM VITAE. NAME: Stephen Harold Arnold Hernandez, PhD, RN CURRICULUM VITAE NAME: Stephen Harold Arnold Hernandez, PhD, RN CONTACT INFORMATION: Address UNM College of Nursing MSC09 5350 1 University of New Mexico Albuquerque, New Mexico 87131-0001 Office Phone

More information

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with

More information

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015 Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet

More information

24 th Annual Conference on Cardiovascular Nursing

24 th Annual Conference on Cardiovascular Nursing 24 th Annual Conference on Cardiovascular Nursing Presented by the American Heart Association s Boston Cardiovascular Nursing Committee Wednesday, April 2, 2014 7:00 am - 3:45 pm Boston Marriott Newton,

More information

Curriculum Vitae. 2100 Statonsburg Road (252)847-5875

Curriculum Vitae. 2100 Statonsburg Road (252)847-5875 Curriculum Vitae 2100 Statonsburg Road (252)847-5875 Greenville, NC 27834 [email protected] Education/Training PGY2 Specialty Practice Residency, Cardiology July 2009-June 2010 Columbus, OH PGY1

More information

FACULTY OF ALLIED HEALTH SCIENCES

FACULTY OF ALLIED HEALTH SCIENCES FACULTY OF ALLIED HEALTH SCIENCES 102 Naresuan University FACULTY OF ALLIED HEALTH SCIENCES has focused on providing strong professional programs, including Medical established as one of the leading institutes

More information

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin. To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation

More information

Attending Physician Attitudes Toward Choice of Oral Anticoagulant for the Treatment of Venous Thromboembolism

Attending Physician Attitudes Toward Choice of Oral Anticoagulant for the Treatment of Venous Thromboembolism Attending Physician Attitudes Toward Choice of Oral Anticoagulant for the Treatment of Venous Thromboembolism NATHAN T. CONNELL, MD, MPH; JAMES N. BUTERA, MD ABSTRACT Until recently, warfarin has been

More information

Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation

Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation Goal Statement Pharmacists and technicians will gain knowledge in the use of target specific oral anticoagulants

More information

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications

More information

Antiplatelet and Antithrombotics From clinical trials to guidelines

Antiplatelet and Antithrombotics From clinical trials to guidelines Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories

More information

Updates to the Alberta Human Services Drug Benefit Supplement

Updates to the Alberta Human Services Drug Benefit Supplement Updates to the Alberta Human Services Drug Benefit Supplement Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone

More information

AMERICAN COLLEGE of CARDIOLOGY

AMERICAN COLLEGE of CARDIOLOGY AMERICAN COLLEGE of CARDIOLOGY CARDIAC CARE ASSOCIATE MEMBERSHIP APPLICATION Registered Nurse Nurse Practitioner Clinical Nurse Specialist Physician Assistant Clinical Pharmacist Improve Patient Care,

More information

New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis

New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,

More information

Coronary CTA in the Emergency Department A Hands-on Workshop

Coronary CTA in the Emergency Department A Hands-on Workshop Coronary CTA in the Emergency Department A Hands-on Workshop November 7-8, 2009 Eden Roc Hotel Miami Beach, Florida Symposium Director Coronary CTA in the Emergency Department: A Hands-on Workshop Target

More information

CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. Las Vegas, Nevada Bellagio March 4 6, 2016. Participating Faculty

CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. Las Vegas, Nevada Bellagio March 4 6, 2016. Participating Faculty CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE Las Vegas, Nevada Bellagio March 4 6, 2016 Participating Faculty Friday, March 4th: 7:30 am - 8:00 am Registration and Hot Breakfast 8:00 am - 9:00 am Pulmonary

More information

About Medicine Specialists of Florida Hospital:

About Medicine Specialists of Florida Hospital: Welcome to Medicine Specialists of Florida Hospital. We look forward to serving you and your family in any way we can. Our physicians and staff strive to offer personalized care to each patient while maintaining

More information

24 th Annual Frontiers in Critical Care Nursing. Presented by UMass Memorial Medical Center Heart and Vascular Center of Excellence

24 th Annual Frontiers in Critical Care Nursing. Presented by UMass Memorial Medical Center Heart and Vascular Center of Excellence 24 th Annual Frontiers in Critical Care Nursing Tuesday May 7, 2013 Presented by Heart and Vascular Center of Excellence $80 Early Registration by March 22 Best Western Royal Plaza Hotel 181 Boston Post

More information

Stroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2

Stroke Risk Scores. CHA 2 DS 2 -VASc. CHA 2 DS 2 -VASc Scoring Table 2 Bleeding/Clotting Risk Evaluation Tools for Atrial Fibrillation Patients Before prescribing anticoagulants, providers should weigh the risk of thrombosis against the risk of bleeding. The tools below can

More information

San Antonio Heart Failure Symposium 2015

San Antonio Heart Failure Symposium 2015 San Antonio Heart Failure Symposium 2015 Continuing Medical Education Saturday, February 28, 2015 Expert Faculty, 8 Hours CME, 8 Hours CEU Comprehensive review and latest updates in: - Heart failure -

More information

xaban) Policy covered: Coverage of following criteria: the following those who meet the or Hip Xarelto is For those impacted by this policy.

xaban) Policy covered: Coverage of following criteria: the following those who meet the or Hip Xarelto is For those impacted by this policy. Xarelto (rivarox xaban) Policy Number: 5.01.575 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Xarelto when it is determined to be medically necessary

More information

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness

More information

Registered Nurse Nurse Practitioner Clinical Nurse Specialist Physician Assistant. Cardiac Care Associate Membership application

Registered Nurse Nurse Practitioner Clinical Nurse Specialist Physician Assistant. Cardiac Care Associate Membership application American College of Cardiology Cardiac Care Associate Membership application Registered Nurse Nurse Practitioner Clinical Nurse Specialist Physician Assistant Improve Patient Care, Increase Facility Performance,

More information

UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient

UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Guidelines for Anticoagulation Initiation and Management Y2014 UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Topic Page Number MEDICATION FLOW AND PATIENT FLOW... 2 AND 3 PARENTERAL ANTICOAGULANTS...

More information

Service Specification Template Department of Health, updated June 2015

Service Specification Template Department of Health, updated June 2015 Service Specification Template Department of Health, updated June 2015 Service Specification No. : 2 Service: Commissioner Lead: Provider Lead: Period: Anti-coagulation monitoring Date of Review: 31 st

More information

PHYSICIANS SAMIA KHOURY, MD PROFESSOR, DIRECTOR, ABU-HAIDAR NEUROSCIENCE INSTITUTE AND MULTIPLE SCLEROSIS CENTER

PHYSICIANS SAMIA KHOURY, MD PROFESSOR, DIRECTOR, ABU-HAIDAR NEUROSCIENCE INSTITUTE AND MULTIPLE SCLEROSIS CENTER 1 PHYSICIANS SAMIA KHOURY, MD PROFESSOR, DIRECTOR, ABU-HAIDAR NEUROSCIENCE INSTITUTE AND MULTIPLE SCLEROSIS CENTER Dr. Samia Khoury is the Jack, Sadie, and David Breakstone Professor of Neurology at Harvard

More information

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,

More information

Anticoagulation before and after cardioversion; which and for how long

Anticoagulation before and after cardioversion; which and for how long Anticoagulation before and after cardioversion; which and for how long Sameh Samir, MD Cardiovascular medicine dept. Tanta faculty of medicine Atrial fibrillation goals of management Identify and treat

More information

Tennessee Chapter Scientific Meeting

Tennessee Chapter Scientific Meeting Tennessee Chapter Scientific Meeting 2016 October 28 29, 2016 Franklin Marriott Cool Springs Franklin, Tennessee Register Online Today! www.cvent.com/d/qfqbcy/4w Keeping App With the Guidelines: Evidence-Based

More information

STEMI & CARDIAC ARREST

STEMI & CARDIAC ARREST STEMI & CARDIAC ARREST CONFERENCE 2015 May 6, 2015 Registration 7:30 am Program 7:50 am 4:00 pm East Carolina Heart Institute at East Carolina University Greenville, NC Jointly Provided by East Carolina

More information

Low Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice

Low Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice Low Molecular Weight Heparin All Wales Medicines Strategy Group (AWMSG) Recommendations and advice Starting Point Low Molecular Weight Heparin (LMWH): Inhibits factor Xa and factor IIa (thrombin) Small

More information

Sanford Health/UNDSMHS Cerebrovascular Symposium

Sanford Health/UNDSMHS Cerebrovascular Symposium Discover. Inspire. Grow. Sanford Health/UNDSMHS Cerebrovascular Symposium January 23, 2016 Ramada Plaza & Suites 1635 42nd Street South Fargo, North Dakota (701) 277-9000 This symposium is supported in

More information

Cardiovascular Subcommittee of PTAC Meeting held 27 February 2014. (minutes for web publishing)

Cardiovascular Subcommittee of PTAC Meeting held 27 February 2014. (minutes for web publishing) Cardiovascular Subcommittee of PTAC Meeting held 27 February 2014 (minutes for web publishing) Cardiovascular Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology

More information